S-1/A: Actuate Therapeutics Files Amendment No. 4 to Form S-1, Outlines IPO Details

Actuate Therapeutics updates its S-1 filing, detailing the initial public offering of 2,777,778 shares of common stock with an estimated price range of $8.00 to $10.00 per share.

Summary

• Actuate Therapeutics has filed Amendment No. 4 to its Form S-1 registration statement with the SEC.
• The company is planning an initial public offering (IPO) of 2,777,778 shares of its common stock.
• The estimated initial public offering price is between $8.00 and $10.00 per share.
• Actuate Therapeutics has applied to list its common stock on the Nasdaq Capital Market under the symbol ACTU.
• The company has granted underwriters an option to purchase up to an additional 416,666 shares to cover over-allotments.
• Top line results from the Phase 2 trial are expected in the first quarter of 2025.
• The company intends to use the net proceeds from this offering, along with its existing cash and cash equivalents, for clinical trials and product development, research and development, clinical manufacturing as well as for working capital and other general corporate purposes.
• The company estimates net proceeds from the offering to be approximately $21.8 million, or $25.3 million if the over-allotment option is exercised in full.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative information. The positive aspects include promising clinical trial results, FDA designations, and plans for future development. The negative aspects include the company's financial losses, dependence on a single product candidate, and the risks associated with clinical development and regulatory approval. Overall, the sentiment is neutral to slightly positive, reflecting the potential of the company's technology but also the significant challenges it faces.

Positives

• The company's lead drug, elraglusib, has been granted Fast Track and Orphan Drug Designations from the FDA for pancreatic cancer.
• The company has generated clinical data from over 500 patients that have been dosed with elraglusib to date.
• The company has completed a Phase 1 healthy volunteer study showing very favorable (>50%) bioavailability after a single dose of Elraglusib Oral Liquid.

Negatives

• The company has incurred significant operating losses since its inception and expects to continue to do so.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The company currently depends entirely on the success of elraglusib, which is its only product candidate.
• The company has a limited operating history and no products approved for commercial sale.

Risks

• The company may not be able to obtain regulatory approval for elraglusib or any future product candidates.
• Clinical trials may not yield sufficiently conclusive results for regulatory agencies to approve the use of the company's products.
• The company may experience delays or difficulties in the enrollment of subjects to its clinical trials.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company will require substantial additional capital to finance its operations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force the company to delay, limit, reduce or terminate its development programs, commercialization efforts or other operations.

Future Outlook

The company plans to use the net proceeds from the offering to fund the research and development of elraglusib, including certain manufacturing activities, and the remainder for working capital and other general corporate purposes. The company estimates that the net proceeds from this offering and its existing cash and cash equivalents will be sufficient to fund its operations for approximately 12 months following the date of this prospectus.

Management Comments

• Management expects to incur significant expenses and operating losses in the foreseeable future, and anticipates these losses will increase substantially as the company continues its development of, seeks regulatory approval for, and potentially commercializes elraglusib, and potentially seeks to discover and develop additional product candidates, utilize third parties to manufacture elraglusib, hire additional personnel, expand and protect its intellectual property, and incur additional costs associated with being a public company.

Industry Context

The document highlights the competitive landscape of the biopharmaceutical industry, particularly in oncology, and the challenges of developing and commercializing new drug products. It also discusses the increasing emphasis on cost-containment initiatives in healthcare, which may put pressure on the pricing and usage of new therapies.

Comparison to Industry Standards

• The document mentions that the mOS in patients with mPDAC is 9-11 months, providing a benchmark for evaluating the potential impact of elraglusib.
• The document compares the mOS of 7.7 months in Part 1 of Actuate-1801 with mOS 8-10 months for other active single agents evaluated in Phase 1 trials.
• The document compares the mOS of 15.3 months for the EE and 11.9 months for the ITT in Actuate-1801 Part 3A with the mOS for GnP alone of 8.5 months in the MPACT trial and 9.2 months in NAPOLI-3, and with the mOS of 11.2 months for FOLFIRINOX.
• The document compares the ORR of 21% for CT in the rEECur phase 3 trial to establish a success threshold for the Actuate-1902 Phase 2 trial in Ewing sarcoma.

Related Party Transactions

• The document discloses transactions with Bios Clinical Opportunity Fund, LP, a fund affiliated with two members of the board of directors of the Company and a majority shareholder, including the issuance of convertible promissory notes.
• The document discloses that Mr. Richard Kenley, Vice President of Manufacturing for the Company, is an unpaid advisor for PBL and his spouse is a shareholder in PBL.

Stakeholder Impact

• Shareholders will be impacted by the dilution resulting from the IPO and potential future equity issuances.
• Employees may be impacted by the company's ability to continue operations and fund its development programs.
• Patients may benefit from the development of new therapies for difficult-to-treat cancers.
• The company's suppliers and manufacturers may be impacted by its ability to fund its operations and continue its development programs.

Next Steps

• Complete the ongoing Elraglusib Injection Phase 2 mPDAC trial (Actuate-1801 Part 3B).
• Complete the existing pediatric refractory cancer Phase 1 dose escalation trial in patients with refractory Ewing sarcoma (Actuate-1902).
• Satisfy the company's funding commitments for ongoing IIT studies for the use of Elraglusib Injection with other chemotherapy agents to treat mPDAC and a separate trial to treat recurrent salivary gland cancer.
• Satisfy the company's obligations under its amended license agreement with UIC to pay accrued interest.
• Finalize development plans and initiate and complete a Phase 1 dose escalation study for the Elraglusib Oral Tablet in patients with advanced, refractory solid cancer.
• Complete the Phase 2 portion of the study in patients with refractory Ewing sarcoma (Actuate-1902).
• Finalize development plans and initiate and enroll patients in a Phase 2 study in refractory metastatic melanoma (Actuate-2401) once the Phase 1 dose escalation study was completed.

Key Dates

Keywords

elraglusib, IPO, clinical trials, pancreatic cancer, GSK-3, Actuate Therapeutics, oncology, FDA, mPDAC, Ewing sarcoma